Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide

Gynecol Oncol. 1983 Apr;15(2):224-9. doi: 10.1016/0090-8258(83)90078-1.

Abstract

Between 1971 and 1979, seventy-four patients with metastatic or advanced recurrent sarcoma of uterine origin were treated with combination chemotherapy consisting of vincristine, actinomycin D, and cyclophosphamide (Cytoxan). The probability of survival at 2 and 5 years was 23 and 15%, respectively. The response rate for patients with measurable disease was 28.9% (15.6% partial responses and 13.3% complete responses). The median duration of a complete response was 16 months and that of a partial response was 5.5 months. The median survival of the complete responders was prolonged when compared to nonresponders.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols*
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / adverse effects
  • Dactinomycin / administration & dosage*
  • Dactinomycin / adverse effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leiomyosarcoma / drug therapy*
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local
  • Prognosis
  • Retrospective Studies
  • Sarcoma / drug therapy*
  • Uterine Neoplasms / drug therapy*
  • Vincristine / administration & dosage*
  • Vincristine / adverse effects

Substances

  • Dactinomycin
  • Vincristine
  • Cyclophosphamide

Supplementary concepts

  • VAC protocol